Role of Different Replacement Fluids During Extracorporeal Treatment in a Pig Model of Sepsis

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 1, 2013, Pages 84-92

  Sauer, Martin ^a   Altrichter, Jens ^a   Mencke, Thomas ^a   Klöhr, Sven ^b   Thomsen, Maren ^a   Kreutzer, Hans J ^a   Nöldge Schomburg, Gabriele ^a   Mitzner, Steffen R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Hospital of Bamberg   (Germany)

Author keywords

Centrifugation; Colloids; Extracorporeal therapy; Plasma; Septic shock

Indexed keywords

FRESH FROZEN PLASMA; GAMMA INTERFERON; HEMOGLOBIN; HETASTARCH; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; LACTIC ACID; PLASMA SUBSTITUTE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL OXYGEN TENSION; ARTICLE; BACTERIAL COUNT; BLOOD FILTRATION; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CENTRIFUGATION; COLLOID; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL PIG; EXTRACORPOREAL CIRCULATION; GRANULOCYTE; HEMATOCRIT; HEMOFILTRATION; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HYPOTENSION; LEUKOCYTE COUNT; LIVER FUNCTION; MEAN ARTERIAL PRESSURE; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPSIS; STAPHYLOCOCCUS AUREUS; SUBSTITUTION THERAPY; SURVIVAL;

ANIMALS; DISEASE MODELS, ANIMAL; EXTRACORPOREAL CIRCULATION; FEMALE; FLUID THERAPY; HETASTARCH; PLASMA SUBSTITUTES; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; SWINE;

EID: 84873418222     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01103.x     Document Type: Article

References (36)

1. Angus DC, Linde-Zwirble WT, Lidicker J etal. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Dellinger RP, Levy MM, Carlet JM etal. Surviving Sepsis Campaign. International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;36:296-327.
3. Rivers E, Nguyen B, Havstad S etal. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
4. Ronco C, Tetta C, Mariano F etal. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
5. Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care 2011;15:205.
6. Busund R, Koukline V, Utrobin U etal. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002;28:1434-9.
7. Iwai H, Nakaki M, Naito T etal. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998;26:873-6.
8. Van Deuren M, Frieling JT, van der Ven-Jongekrijg J etal. Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effects of plasma exchange. Clin Infect Dis 1998;26:918-23.
9. Stegmayr BG, Banga R, Berggren L etal. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003;31:1730-6.
10. Sauer M, Altrichter A, Mencke T etal. Plasma separation by centrifugation and subsequent plasma filtration: impact on survival in a pig model of sepsis. Ther Apher Dial 2012;16:205-12.
11. Lee PA, Weger GW, Pryor RW etal. Effects of filter pore-size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicaemia in immature swine. Crit Care Med 1998;26:730-7.
12. Lee PA, Matson JR, Pryor RW, Hinshaw LB. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993;21:914-24.
13. Hinshaw LB, Taylor FB, Chang ACK etal. Staphylococcus aureus-induced shock: a pathophysiologic study. Circ Shock 1988;26:257-65.
14. Ronco C, Inguaggiato P, D'Intini V etal. The role of extracorporeal therapies in sepsis. J Nephrol 2003;16:34-41.
15. Bellomo R, Honoré PM, Matson J etal. Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs 2005;28:450-8.
16. Cole L, Bellomo R, Hart G etal. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
17. Payen D, Mateo J, Cavaillon JM etal. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009;37:803-10.
18. Sykora R, Chvojka J, Krouzecky A etal. Coupled plasma filtration adsorption in experimental peritonitis-induced septic shock. Shock 2009;31:473-80.
19. Eguchi Y. Plasma dia-filtration for severe sepsis. Contrib Nephrol 2010;166:142-9.
20. Reeves JH, Butt WW, Shann F etal. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999;27:2096-104.
21. Levy H, Ash SR, Knab W etal. Systemic inflammatory response syndrome treatment by powdered sorbent apheresis: the biologic-detoxification plasma filtration system. ASAIO J 1998;44:M659-65.
22. Ronco C, Brendolan A, Lonneman G etal. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-5.
23. Korach JM, Berger P, Giraud C, Le Perff-Desmann C, Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med 1998;24:452-8.
24. Brecher ME, Owen HG, Bandarenko N. Alternatives to albumin: starch replacement for plasma exchange. J Clin Apher 1997;12:146-53.
25. Arslan Ö, Arat M, Tek I, Ayyildiz E, Ilhan O. Therapeutic plasma exchange in a single center: Ibni Sina experience. Transfus Apher Sci 2004;30:181-4.
26. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007; CD:000567.
27. Brunkhorst FM, Engel C, Bloos F etal. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
28. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-7.
29. Schortgen F, Lacherade JC, Bruneel F etal. Effects of hydroxyethylstarch and gelatine on renal function in severe sepsis: a multicentre randomized study. Lancet 2001;357:911-16.
30. Dart AB, Mutter TC, Ruth CA etal. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010; CD:0007594.
31. Franz A, Braunlich P, Gamsjager T etal. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 2001;92:1402-7.
32. de Jonge E, Levi M, Buller HR. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med 2001;27:1825-9.
33. Innerhofer P, Fries D, Markreiter J etal. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 2002;95:858-65.
34. Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolyses in human and rabbit plasma. J Heart Lung Transplant 2006;25:1344-52.
35. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475-82.
36. Guignant C, Lepape A, Huang X etal. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfuctions in septic shock patients. Crit Care 2011;15:R99.